Combination vs. Monotherapy for MBC: No Survival Benefit (n=2,490)
{"Image DocumentName": "Combination vs. Monotherapy for MBC: No Survival Benefit (n=2,490)", "Image ImageDescription": "APPH-1 ONLABEL Abraxane Slides. Combination vs. Monotherapy for MBC: No Survival Benefit (n=2,490) 3/27/2017 9:33 PM. Dox + Paclitaxel = Single Agents Sequentially. (Sledge, J Clin Oncol 2003) FEC then MV = Epirubicin then Mitomycin C. (Joensuu, J Clin Oncol 1998) Taxotere > Mitomycin C + Vinblastine. (Nabholtz, J Clin Oncol 1999) Taxol > CMFP. (Bishop, J Clin Oncol 1998) FEC = Mitoxantrone. (Heidemann, Ann Oncol 2002) Dox + Vinorelbine = Doxorubicin. (Norris, J Clin Oncol 2000) Epirubicin + Vinorelbine = Epirubicin. In fact, there exists a high level of evidence-based medicine to support the approach of single agent chemotherapy for metastatic breast cancer. The 6 randomized trials listed here represent a larger number of patients than in the Fossati meta-analysis, and none showed a survival advantage for the use of combinations over single agents. In the interest of focusing on the 4 trials at hand, I will not examine these trials in detail here. Suffice it to say that in most of these trials, there were neither higher response rates nor longer time to progression for combinations versus the single agent strategy. Toxicities were generally greater for combination therapy, and where assessed, QOL for combination therapy was either equal to or inferior to that experienced during monotherapy. Ejlertsen, J Clin Oncol 2004.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}